X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs FRESENIUS KABI ONCO. - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA FRESENIUS KABI ONCO. ABBOTT INDIA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 44.5 22.1 200.9% View Chart
P/BV x 11.1 3.1 356.7% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ABBOTT INDIA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
FRESENIUS KABI ONCO.
Mar-13
ABBOTT INDIA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs6,015176 3,417.6%   
Low Rs3,70779 4,722.3%   
Sales per share (Unadj.) Rs1,236.937.7 3,282.2%  
Earnings per share (Unadj.) Rs122.25.1 2,398.9%  
Cash flow per share (Unadj.) Rs129.06.7 1,918.4%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs521.242.5 1,225.2%  
Shares outstanding (eoy) m21.25158.23 13.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.93.4 116.4%   
Avg P/E ratio x39.825.0 159.2%  
P/CF ratio (eoy) x37.718.9 199.1%  
Price / Book Value ratio x9.33.0 311.8%  
Dividend payout %28.60-   
Avg Mkt Cap Rs m103,29620,135 513.0%   
No. of employees `0003.01.2 256.6%   
Total wages/salary Rs m3,370703 479.2%   
Avg. sales/employee Rs Th8,891.85,176.2 171.8%   
Avg. wages/employee Rs Th1,140.0610.4 186.8%   
Avg. net profit/employee Rs Th878.3699.6 125.6%   
INCOME DATA
Net Sales Rs m26,2845,963 440.8%  
Other income Rs m50418 2,802.2%   
Total revenues Rs m26,7895,981 447.9%   
Gross profit Rs m3,6651,430 256.3%  
Depreciation Rs m144258 56.0%   
Interest Rs m8-26 -31.2%   
Profit before tax Rs m4,0171,216 330.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,421342 415.3%   
Profit after tax Rs m2,596806 322.2%  
Gross profit margin %13.924.0 58.1%  
Effective tax rate %35.428.1 125.7%   
Net profit margin %9.913.5 73.1%  
BALANCE SHEET DATA
Current assets Rs m14,4465,102 283.2%   
Current liabilities Rs m4,7252,385 198.1%   
Net working cap to sales %37.045.6 81.2%  
Current ratio x3.12.1 143.0%  
Inventory Days Days51150 34.3%  
Debtors Days Days20113 17.3%  
Net fixed assets Rs m1,1135,148 21.6%   
Share capital Rs m213158 134.3%   
"Free" reserves Rs m10,8086,556 164.9%   
Net worth Rs m11,0766,732 164.5%   
Long term debt Rs m0952 0.0%   
Total assets Rs m16,24110,388 156.3%  
Interest coverage x497.0-45.8 -1,085.6%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.60.6 281.9%   
Return on assets %16.07.5 213.6%  
Return on equity %23.412.0 195.8%  
Return on capital %36.314.6 248.9%  
Exports to sales %0.674.5 0.8%   
Imports to sales %12.624.8 51.0%   
Exports (fob) Rs m1624,441 3.6%   
Imports (cif) Rs m3,3221,477 224.9%   
Fx inflow Rs m2685,298 5.1%   
Fx outflow Rs m3,9271,772 221.6%   
Net fx Rs m-3,6593,525 -103.8%   
CASH FLOW
From Operations Rs m2,5141,274 197.3%  
From Investments Rs m-800-1,204 66.4%  
From Financial Activity Rs m-803-196 409.4%  
Net Cashflow Rs m912-126 -722.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 7.9 0.3 2,633.3%  
FIIs % 0.1 9.6 1.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 9.1 187.9%  
Shareholders   18,270 42,599 42.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  MERCK LTD  SANOFI INDIA  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS